Prophylaxis use among males with haemophilia B in the United States

M. Ullman, Q. C. Zhang, S. D. Grosse, Michael Recht, J. M. Soucie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1-5% of normal and <1% of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample. Aim: This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics. Methods: Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention's Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2-79 years who were seen at 135 federally funded haemophilia treatment centres. Results: Prevalence of prophylactic treatment in our sample was 35% among children and youth (ages 2-19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access. Conclusions: Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.

Original languageEnglish (US)
JournalHaemophilia
DOIs
StateAccepted/In press - 2017

Fingerprint

Hemophilia B
Hemophilia A
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Hispanic Americans
Population
Body Mass Index
Cross-Sectional Studies
Demography
Delivery of Health Care

Keywords

  • BMI
  • Ethnicity
  • Haemophilia B
  • Obesity
  • Overweight
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Ullman, M., Zhang, Q. C., Grosse, S. D., Recht, M., & Soucie, J. M. (Accepted/In press). Prophylaxis use among males with haemophilia B in the United States. Haemophilia. https://doi.org/10.1111/hae.13317

Prophylaxis use among males with haemophilia B in the United States. / Ullman, M.; Zhang, Q. C.; Grosse, S. D.; Recht, Michael; Soucie, J. M.

In: Haemophilia, 2017.

Research output: Contribution to journalArticle

Ullman, M. ; Zhang, Q. C. ; Grosse, S. D. ; Recht, Michael ; Soucie, J. M. / Prophylaxis use among males with haemophilia B in the United States. In: Haemophilia. 2017.
@article{d1a6b73f23fa4f759a3065346a238445,
title = "Prophylaxis use among males with haemophilia B in the United States",
abstract = "Introduction: Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1-5{\%} of normal and <1{\%} of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample. Aim: This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics. Methods: Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention's Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2-79 years who were seen at 135 federally funded haemophilia treatment centres. Results: Prevalence of prophylactic treatment in our sample was 35{\%} among children and youth (ages 2-19) and 14{\%} among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access. Conclusions: Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.",
keywords = "BMI, Ethnicity, Haemophilia B, Obesity, Overweight, Prophylaxis",
author = "M. Ullman and Zhang, {Q. C.} and Grosse, {S. D.} and Michael Recht and Soucie, {J. M.}",
year = "2017",
doi = "10.1111/hae.13317",
language = "English (US)",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Prophylaxis use among males with haemophilia B in the United States

AU - Ullman, M.

AU - Zhang, Q. C.

AU - Grosse, S. D.

AU - Recht, Michael

AU - Soucie, J. M.

PY - 2017

Y1 - 2017

N2 - Introduction: Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1-5% of normal and <1% of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample. Aim: This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics. Methods: Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention's Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2-79 years who were seen at 135 federally funded haemophilia treatment centres. Results: Prevalence of prophylactic treatment in our sample was 35% among children and youth (ages 2-19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access. Conclusions: Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.

AB - Introduction: Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1-5% of normal and <1% of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample. Aim: This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics. Methods: Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention's Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2-79 years who were seen at 135 federally funded haemophilia treatment centres. Results: Prevalence of prophylactic treatment in our sample was 35% among children and youth (ages 2-19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access. Conclusions: Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.

KW - BMI

KW - Ethnicity

KW - Haemophilia B

KW - Obesity

KW - Overweight

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85026799011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026799011&partnerID=8YFLogxK

U2 - 10.1111/hae.13317

DO - 10.1111/hae.13317

M3 - Article

C2 - 28780772

AN - SCOPUS:85026799011

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

ER -